Janssen will conduct Risperdal-Zyprexa comparative trial in response to Lilly study presented at ACNP.
JANSSEN PLANNING RISPERDAL HEAD-TO-HEAD TRIAL WITH ZYPREXA, the company said in response to the announcement of the interim results from a Lilly-conducted comparative schizophrenia trial. The study presented at the American College of Neuropsychopharmacology in San Juan, Puerto Rico on Dec. 11 by Lilly's Pierre Tran, MD, concluded that Zyprexa (olanzapine) "significantly outperforms risperidone [Risperdal]" in efficacy, extrapyramidal symptom incidence and minimal prolactin elevation.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth